Małgorzata D Klimowicz-Bodys1, Katarzyna Płoneczka-Janeczko1, Michał Czopowicz2, Mirosław Paweł Polak3, Agnieszka Lachowicz-Wolak1, Krzysztof Rypuła1. 1. Division of Infectious Diseases of Animals and Veterinary Administration, Department of Epizootiology and Clinic of Birds and Exotic Animals, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, pl. Grunwaldzki 45, 50-366 Wroclaw, Poland. 2. Division of Veterinary Epidemiology and Economics, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, ul. Nowoursynowska 159c, 02-776 Warsaw, Poland. 3. Department of Virology, National Veterinary Research Institute, al. Partyzantów 57, 24-100 Puławy, Poland.
Abstract
(1) Background: The objective of the study was to evaluate the long-term antibody response of dairy cows to a single dose of a commercial modified-live virus (MLV) vaccine against bovine viral diarrhea (Mucosiffa® CEVA Sante Animale, Liburne, France). (2) Methods: The study was carried out in a dairy cattle herd counting 290 animals negative for bovine viral diarrhoea virus (BVDV). The vaccination was implemented following the manufacturer's instructions. Twelve dairy cows were randomly selected before the study, and blood samples were collected right before the vaccination and then 12 times at 1-month intervals. The serum samples were screened using a virus neutralization test (VNT) and ELISA. (3) Results: Both tests showed that antibody titers increased significantly in all animals within the first month post-vaccination, and continued to increase significantly until the second (VNT) and third (ELISA) month post-vaccination. Antibody titers remained high and stable until the end of the study. Moreover, cows did not show any adverse reactions or clinical symptoms of the disease. (4) Conclusion: The results of this study indicated that the administration of one dose MLV vaccine was able to stimulate long-lasting (12-months) and strong antibody response in all vaccinated cows.
(1) Background: The objective of the study was to evaluate the long-term antibody response of dairy cows to a single dose of a commercial modified-live virus (MLV) vaccine against bovine viral diarrhea (Mucosiffa® CEVA Sante Animale, Liburne, France). (2) Methods: The study was carried out in a dairy cattle herd counting 290 animals negative for bovine viral diarrhoea virus (BVDV). The vaccination was implemented following the manufacturer's instructions. Twelve dairy cows were randomly selected before the study, and blood samples were collected right before the vaccination and then 12 times at 1-month intervals. The serum samples were screened using a virus neutralization test (VNT) and ELISA. (3) Results: Both tests showed that antibody titers increased significantly in all animals within the first month post-vaccination, and continued to increase significantly until the second (VNT) and third (ELISA) month post-vaccination. Antibody titers remained high and stable until the end of the study. Moreover, cows did not show any adverse reactions or clinical symptoms of the disease. (4) Conclusion: The results of this study indicated that the administration of one dose MLV vaccine was able to stimulate long-lasting (12-months) and strong antibody response in all vaccinated cows.
Authors: S P Rodning; M D Givens; M S D Marley; Y Zhang; K P Riddell; P K Galik; T L Hathcock; J A Gard; J W Prevatt; W F Owsley Journal: Theriogenology Date: 2012-10-15 Impact factor: 2.740
Authors: Krzysztof Rypuła; Katarzyna Płoneczka-Janeczko; Michał Czopowicz; Malgorzata D Klimowicz-Bodys; Sergey Shabunin; Georges Siegwalt Journal: Animals (Basel) Date: 2020-01-31 Impact factor: 2.752